Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer. 2019 Feb 8;2019:11-20. doi: 10.2147/LCTT.S179349
Masaquel C, Rothwell B, Bhaila R, Copley-Merriman C, Wolowacz S, Aguiar-Ibanez R, Patel N, Liu FX. A systematic review of utility estimates in melanoma in the adjuvant setting. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.
Copley-Merriman C, Stevinson K, Liu FX, Wang J, Mauskopf J, Zimovetz EA, Chmielowski B. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Medicine. 2018 Aug;97(31):e11736. doi: 10.1097/MD.0000000000011736
Barrows SM, Cai B, Copley-Merriman C, Wright KR, Castro CV, Soufi-Mahjoubi R. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta-Anal. 2018 Jun 28;6(2):9-20.
Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic Literature Review (SLR) of sequencing of Anaplastic Lymphoma Kinase (ALK) inhibitors in ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49-50. doi: 10.1016/j.jval.2018.04.291
Masaquel C, Hurley D, Barnett B, Krieger T, Pearson I, Copley-Merriman C, Kaye JA, Moy B. Clinical and economic burden of HER2-positive breast cancer recurrence in the US: a literature review. Poster presented at the 2017 San Antonio Breast Cancer Symposium; December 7, 2017. San Antonio, TX.
Barrows SM, Cai B, Wright K, Castro CV, Kaye JA, Copley-Merriman C, Soufi-Mahjoubi R. Systematic literature review of octreotide's antitumor effects in neuroendocrine tumors. Poster presented at the 2017 North American Neuroendocrine Tumor Society Annual Symposium; October 19, 2017. Philadelphia, PA.
Winnette R, Hess LM, Nicol SJ, Tai DF, Copley-Merriman C. The patient experience with soft tissue sarcoma: a systematic review of the literature. Patient. 2017 Apr;10(2):153-62. doi: 10.1007/s40271-016-0200-1
Masaquel C, Jerusalem G, Copley-Merriman K, Ray D, Higuchi K, Caceres V. Economic burden of advanced breast cancer. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A146.
Hess LM, Winnette R, Nicol S, Tai DF, Copley-Merriman K. Understanding the patient experience with soft tissue sarcoma: a systematic review of the literature. Poster presented at the 2016 American Society of Clincial Oncology Quality Care Symposium; February 26, 2016. Phoenix, AZ.
Khan S, Zimovetz E, Healey P, Copley-Merriman K. Biologics in ulcerative colitis (UC): treatment guidelines, health technology assessments (HTA). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. [abstract] Value Health. 2015 Nov; 18(7):A633.
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Clark MJ, Harris N, Griebsch I, Kaschinski D, Copley-Merriman C. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union. Health Qual Life Outcomes. 2014 Jul 4;12(1):104.
Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375
Xu J, Evans J, Coon C, Copley-Merriman K, Su Y. Measuring patient-reported outcomes in advanced gastric cancer. Ecancermedicalscience. 2013;7:351. doi: 10.3332/ecancer.2013.351.
Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012 Dec 1;5:151-63.
Kiladjian JJ, Gisslinger H, Passamonti F, Neiderwieser D, Medelson E, Sirulnik LA, Copley-Merriman K, Zhou X. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasms; October 4, 2012. Previously presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Zhou X, Wang J, Zhang J, Copley-Merriman K, Torigoe Y, Reyes C. Symptoms and toxicity of rituximab maintenance (R-M) versus observation (OBS) following rituximab plus chemotherapy in patients with follicular lymphoma. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):3661. doi: 10.1182/blood.V118.21.3661.3661
Colosia AD, Peltz G, Pohl G, Liu E, Copley-Merriman K, Khan S, Kaye JA. A review and characterization of the various perceptions of quality cancer care. Cancer. 2011 Mar 1;117(5):884-96.
Khan SB, Peltz G, Pohl G, Liu E, Copley-Merriman K, Colosia AD. Impact of patient/provider communications on quality of care for cancer. Poster presented at the 3rd Conference of the American Association for Cancer Research; October 2010.
Copley-Merriman K, Peltz G, Pohl G, Liu E, Kaye JA. Impact of race/ethnicity and health insurance status on quality of care for cancer. Poster presented at the Annual Meeting of the American Society of Clinical Oncology; June 2010.
Mladsi DM, Irish WD, Copley-Merriman K, Bhandary D. Statistical measures of treatment effects in oncology: what are we missing? Presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.
Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-Maynard D, Copley-Merriman K, Hsu MA. Development of the cancer chemotherapy satisfaction questionnaire (CCSQ): item generation and content validity testing. Value Health. 2005 Nov;8(Suppl 1):S41-53.
Copley-Merriman K, Jackson J, Boyer JG, Cappelleri J, DeMarinis R, DiCesare J. Industry perspective regarding outcomes research in oncology. New York: NY. Cambridge University Press; 2004. p.623-38.
Dorazio P, Keininger DL, Abetz L, Coombs JH, Copley-Merriman K, Bury-Maynard DP, Hsu MA. Comparing patient and nurse perspectives on cancer treatment: results from a qualitative study. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; September 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 Sep; 22:778.
Coombs JH, Abetz L, Keininger DL, Earle CC, Copley-Merriman K, Hsu M-A, Bury-Maynard DP. Development of the Cancer Chemotherapy Satisfaction Questionnaire (CCSQ): part I: item-generation and content validity testing. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:545.
Osoba D, Hsu M-A, Copley-Merriman K, Johnson FR, Hauber AB, Coombs J. Cancer patients' preferences for health-related quality of life (HRQOL) domains during treatment. Poster presented at the 2003 Annual Meeting of the American Society of Clinical Oncology; May 2003.
Clark M, Copley-Merriman K, Coombs JH, Von Pawel J, Koschel G, Pauer LR. Patient reported outcomes (symptoms, functioning, and quality of life [QOL]) in a randomized Phase II study of CI-994 plus carboplatin and paclitaxel (C/T) vs placebo (PBO) plus C/T in the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC). Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:687.
McBurney C, Coombs J, Hsu M, Abetz L, Keininger D, Copley-Merriman K. An appraisal of treatment satisfaction and patient preference assessments in patients diagnosed with cancer. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2003. [abstract] Value Health. 5(3):201.
Coombs J, McBurney C, Gondek K, Copley-Merriman C. Evidence of patient reported outcomes in labeling for oncology products: evaluation of United States and European labels. Mapi Quality of Life Newsletter. 2002 Oct;29:1-3.
Copley-Merriman K, Pawel J, Shepard F, Kimmel K, Gulyas S, Eckert S. Randomized phase 2 study of the oral histone deacetylase inhibitor ci-994 plus gemcitabine vs. placebo plus gemcitabine in second-line nsclc: health-related quality of life results. Poster presented at the American Society of Clinical Oncology; May 2002. Orlando, FL.